Kenvue Inc. (NYSE:KVUE) Shares Sold by Brandywine Global Investment Management LLC

Brandywine Global Investment Management LLC reduced its position in Kenvue Inc. (NYSE:KVUE) by 93.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 87,743 shares of the company’s stock after selling 1,318,066 shares during the period. Brandywine Global Investment Management LLC’s holdings in Kenvue were worth $1,873,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. increased its holdings in Kenvue by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company’s stock valued at $4,665,908,000 after purchasing an additional 1,636,741 shares in the last quarter. State Street Corp grew its stake in shares of Kenvue by 16.8% in the third quarter. State Street Corp now owns 127,213,940 shares of the company’s stock valued at $2,942,458,000 after buying an additional 18,283,473 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Kenvue by 0.9% in the third quarter. Geode Capital Management LLC now owns 44,677,077 shares of the company’s stock valued at $1,029,810,000 after buying an additional 399,846 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Kenvue by 2.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 24,972,777 shares of the company’s stock valued at $533,169,000 after buying an additional 561,570 shares during the period. Finally, Norges Bank acquired a new position in Kenvue during the 4th quarter worth approximately $521,348,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Down 0.0 %

KVUE stock opened at $23.87 on Thursday. The firm has a market cap of $45.62 billion, a price-to-earnings ratio of 45.04, a PEG ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The firm has a fifty day moving average price of $22.50 and a two-hundred day moving average price of $22.47. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Research analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.44%. Kenvue’s payout ratio is currently 154.72%.

Analysts Set New Price Targets

A number of research firms have recently issued reports on KVUE. Barclays lifted their price objective on shares of Kenvue from $21.00 to $23.00 and gave the company an “equal weight” rating in a research note on Thursday, March 27th. UBS Group cut their price objective on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday, February 7th. Canaccord Genuity Group raised their target price on Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. Piper Sandler boosted their price target on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research note on Monday, February 24th. Finally, Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and reduced their price target for the company from $25.00 to $24.00 in a report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $24.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.